Combined Response Index News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Combined response index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Combined Response Index Today - Breaking & Trending Today

Kadmon Holdings, Inc.: Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis


(0)
NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company s ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs.
The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg twice daily (BID). The primary endpoint is the Combined Response Index for Systemic Sclerosis (CRISS) score. The Company plans to present initial data from this study by year-end 2021.
In addition to the KD025-215 trial, an ongoing, double-blind, placebo-controlled Phase 2 clinical trial of belumosudil (KD025-209) is currently enrolling 60 adults with dcSSc. Patients are randomized to receive belumosudil 200 mg once daily (QD), belumosudil 200 mg BID or placebo. ....

United States , Harlanw Waksal , Ellen Cavaleri , Exchange Commission , Kadmon Holdings Inc , Drug Administration , Kadmon Holdings , Combined Response Index , Systemic Sclerosis , Orphan Drug Designation , Priority Review , New Drug Application , Prescription Drug User Fee Act , Time Oncology Review , Project Orbis , Breakthrough Therapy Designation , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , ஒருங்கிணைந்த பதில் குறியீட்டு , முறையான ஸ்க்லரோசிஸ் , ஆர்ஃபந் மருந்து பதவி , ப்ரையாரிடீ விமர்சனம் , புதியது மருந்து விண்ணப்பம் , ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் , நேரம் புற்றுநோயியல் விமர்சனம் ,